AZD2461: Novel PARP Inhibitor Advancing Breast Cancer Research

Executive Summary: AZD2461 is a next-generation PARP inhibitor with an in vitro IC50 of 5 nM against PARP-1, displaying robust cytotoxicity in MCF-7 and SKBR-3 breast cancer cell lines (APExBIO, product page). The compound induces cell cycle arrest at the G2 phase, reduces the S phase population, and is less susceptible to P-glycoprotein-mediated efflux than olaparib, supporting its use in drug-resistant cancer models (Schwartz 2022, DOI). AZD2461 significantly prolongs relapse-free survival in BRCA1-deficient mouse models and is well-tolerated over long-term administration. Its high solubility in DMSO and ethanol, but not water, and its stability at -20°C make it suitable for preclinical workflows. These features position AZD2461 as a leading option for translational breast cancer research and DNA repair pathway interrogation.

Biological Rationale

Poly (ADP-ribose) polymerase (PARP) enzymes, especially PARP-1, are central to the cellular response to DNA damage. PARP-1 detects DNA single-strand breaks and catalyzes the addition of ADP-ribose polymers, facilitating DNA repair and maintaining genome stability (Schwartz 2022). Inhibition of PARP-1 impairs DNA repair, leading to cell death, particularly in cancer cells deficient in homologous recombination repair, such as those with BRCA1 mutations. Targeting PARP signaling is an established therapeutic strategy in oncology, especially for breast and ovarian cancers. Overcoming intrinsic and acquired drug resistance, including via P-glycoprotein (Pgp) efflux mechanisms, remains a major research focus in optimizing PARP inhibitor efficacy.

Mechanism of Action of AZD2461

AZD2461 functions as a selective PARP inhibitor, binding to PARP-1 and preventing its enzymatic activity. The compound has a molecular weight of 395.43 and the chemical formula C₂₂H₂₂FN₃O₃ (APExBIO). In cultured MCF-7 and SKBR-3 breast cancer cells, AZD2461 reduces viable cell numbers in both concentration- and time-dependent manners at 5–50 μM over 48–72 hours. Mechanistically, AZD2461 induces cell cycle arrest, increasing the proportion of cells in the G2 phase and reducing those in S phase, a hallmark of DNA damage response activation. In vivo, AZD2461 inhibits PARP enzymatic activity for several hours post-administration in KB1P mouse tumor models, with poly (ADP-ribose) levels returning to baseline within 24 hours. Its lower affinity for Pgp, relative to olaparib, allows for greater intracellular retention and efficacy in resistant tumor cells (Schwartz 2022).

Evidence & Benchmarks

• AZD2461 inhibits PARP-1 with an in vitro IC50 of 5 nM, outperforming many first-generation PARP inhibitors (Schwartz 2022).
• In human breast cancer cell lines (MCF-7, SKBR-3), AZD2461 induces cytotoxicity in a dose- and time-dependent manner, with significant reductions in viable cells at 5–50 μM after 48–72 hours (Schwartz 2022).
• Cell cycle analysis demonstrates G2 phase arrest and decreased S phase fraction following AZD2461 treatment (Schwartz 2022).
• In BRCA1-mutated KB1P mouse tumor models, AZD2461 suppresses PARP activity for several hours and extends median relapse-free survival with long-term use (Schwartz 2022).
• AZD2461 exhibits lower affinity for P-glycoprotein compared to olaparib, reducing the likelihood of drug efflux-mediated resistance (Schwartz 2022).

For a comparative mechanistic perspective, see AZD2461: Advancing Breast Cancer Research, which reviews PARP-1 inhibition and translational strategies. This article extends those findings by focusing on quantitative cytotoxicity benchmarks and resistance mechanisms.

Applications, Limits & Misconceptions

AZD2461 is used in both in vitro and in vivo models to interrogate DNA repair pathways and evaluate anti-cancer drug responses. Its efficacy in BRCA1-deficient contexts and lower susceptibility to Pgp-mediated efflux make it especially useful in breast cancer research. Researchers should note its poor water solubility but high solubility in DMSO (≥16.35 mg/mL) and ethanol (≥45.2 mg/mL), and the requirement for storage at -20°C. While AZD2461 offers advantages over earlier PARP inhibitors, it is not universally effective in all cancer types or in cells with intact homologous recombination repair mechanisms.

Common Pitfalls or Misconceptions

• AZD2461 is not effective in cancer cells with functional BRCA1/2 and homologous recombination repair.
• It is insoluble in aqueous buffers; improper solvent use can cause precipitation and assay variability.
• AZD2461 is not a pan-PARP inhibitor; its primary target is PARP-1, not all PARP family members.
• Long-term exposure beyond recommended concentrations or storage above -20°C may reduce compound stability and efficacy.
• While it shows reduced Pgp affinity, multidrug resistance can still occur via other mechanisms.

For troubleshooting and application-specific workflows, AZD2461: Novel PARP Inhibitor Transforming Breast Cancer Research provides detailed protocols. The present article clarifies the boundaries of efficacy and solvent compatibility relative to such guides.

Workflow Integration & Parameters

AZD2461 is supplied as a solid and should be dissolved in DMSO or ethanol, not water. Recommended working concentrations for cell culture assays are 5–50 μM, with incubation periods of 48–72 hours. Solutions are best prepared fresh and used promptly. For in vivo work, dosing regimens should be based on published mouse model studies, with monitoring of PAR levels post-administration. AZD2461 is available as SKU A4164 from APExBIO (product page), with comprehensive documentation on storage and handling. For advanced application guidance, see AZD2461: Redefining PARP-1 Inhibition and Drug Resistance, which this article updates with benchmarked quantitative results in breast cancer models.

Conclusion & Outlook

AZD2461 represents a significant advance in PARP inhibitor development for breast cancer and BRCA1-mutated tumor research. Its low IC50, cytotoxicity in relevant cell lines, and reduced Pgp-mediated resistance highlight its translational potential. As APExBIO’s A4164 kit, it enables robust preclinical studies of DNA repair, cell cycle arrest, and drug resistance. Ongoing research will clarify its role in combination therapies and resistance mechanisms in broader cancer contexts. For further reading on future directions in PARP signaling pathway modulation with AZD2461, see AZD2461 and the Future of PARP Signaling Pathway Modulation; this article provides updated, evidence-based parameters and practical boundaries.